Intravenous high-dose immunotherapy: practical recommendations for use in the treatment of neurological disimmune diseases
https://doi.org/10.17650/2222-8721-2015-5-4-16-23
Abstract
Current publication summarizes main indications and benefits of intravenous high-dose immunotherapy (IHI) in the treatment of various autoimmune diseases of the peripheral nervous system. Available products of intravenous immunoglobulin (IVIG) on the Russian market are reviewed. Tactics for choosing optimal medication for IHI based on its effectiveness and safety are analyzed. Dosage calculation and way of administration of IVIG are described, beeing of a high practical value in neurologist’s daily work.
About the Authors
N. A. Suponeva
Research Center of Neurology, 80 Volokolamskoe Shosse, Moscow, 125367, Russia
Russian Federation
Russian Federation
D. A. Grishina
Research Center of Neurology, 80 Volokolamskoe Shosse, Moscow, 125367, Russia
Russian Federation
Russian Federation
References
1. Пирадов М.А., Супонева Н.А. Синдром Гийена–Барре: диагностика и лечение. Руководство для врачей. М.: МЕДпресс-информ, 2011. 200 с. [Piradov M.A., Suponeva N.A. The Guillain–Barré syndrome: diagnosis and treatment. A guide for physicians. Moscow: MEDpress-inform, 2011. 200 p. (In Russ.)].
2. Gilhus N.E., Barnes M.P., Brainin M. Multi focal Motor Neuropathy, in European Handbook of Neurological Management. Wiley-Blackwell, Oxford, UK, 2010. 2nd еd. Vol. 1, ch. 21.
3. Elovaaraa S., Apostolskib P., van Doorn et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008;15:893–908.
4. Van der Meché F.G., Schmitz P.I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain- Barré Study Group. N Engl J Med 1992;326(17):1123–9.
5. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barré syndrome. Plasma Exchange/Sandoglobulin Guillain– Barré Syndrome Trial Group. Lancet 1997;349(9047):225–30.
6. Van Schaik I.N., Winer J.B., de Haan R., Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002;2.
7. Супонева Н.А., Пирадов М.А., Гнедовская Е.В. Качество медицинской помощи больным с синдромом Гийена–Барре в России. Материалы первой учредительной конференции РОО «Общество специалистов по нервно-мышечным болезням» «Актуальные вопросы диагностики и лечения нервно-мышечных болезней». 2012. С. 41. [Suponeva N.A., Piradov M.A., Gnedovskay E.V. Quality medical care for patients with Guillain–Barre syndrome in Russia. Proceedings of the first inaugural conference of the NGO “Society of neuromuscular diseases” “Topical issues of diagnosis and treatment of neuromuscular diseases”. 2012. S.41. (In Russ.)].
8. Teschner W., Butterweck H.A., Auer W. et al. A new liquid, intravenous immunoglobulin product (IGIV 10 %) highly purified by a stateof- the-art process. Vox Sang. 2007;92(1):42–55.
9. Lebing W., Remington K.M., Schreiner C., Paul H.I. Properties of a new intravenous immunoglobulin (IGIV-C, 10 %) produced by virus inactivation with caprylate and column chromatography. Vox Sang 2003;84(3):193–201.
10. Donofrio P.D., Bril V., Dalakas M.C. et al. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. IGIV-C CIDP Efficacy (ICE) Study Group. Arch Neurol 2010;67:1082–8.
11. Kuitwaard K., van der Berg L.H., Vermeulen M. et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2010;81:1374–9.
12. Schiff R.I., Williams L.W., Nelson R.P. et al. Multi-centre crossover comparison of safety and efficacy of Intraglobin-F with Gamimune- N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol 1997;17:21–8.
13. Dantal J. Intravenous Immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol 2013;38:275–84.
14. Супонева Н.А., Пирадов М.А. Внутривенная иммунотерапия в неврологии. М.: Горячая линия телеком, 2013. 320 с. [Suponeva N.A., Piradov M.A. Intravenous immunotherapy in neurology. Moscow: Hot Line Telecom, 2013. 320 p. (In Russ.)].
15. Lenk C., Duttge G. Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag 2014;10:537–46.
Review
For citations:
Suponeva N.A., Grishina D.A. Intravenous high-dose immunotherapy: practical recommendations for use in the treatment of neurological disimmune diseases. Neuromuscular Diseases. 2015;5(4):16-23. (In Russ.) https://doi.org/10.17650/2222-8721-2015-5-4-16-23
Views:
2077
Email this article 